Then, on May 1, 2024, Metagenomi announced that it and Moderna, Inc. had "mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1)," and that the "rights to develop the ...

Controlling the dissolved oxygen in bioreactors sets the stage for developing new treatments for liver disease.

Our expert team reviews products in dedicated test rooms, to help you make the best choice for your budget. Find out more about how we test. You don’t need to set eyes on Pro-Ject’s Primary E ...

Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States The Cancer Institute of New Jersey, New ...